Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
14.32
-0.42 (-2.85%)
At close: Mar 6, 2026, 4:00 PM EST
14.17
-0.15 (-1.05%)
After-hours: Mar 6, 2026, 6:58 PM EST
Aurinia Pharmaceuticals Revenue
In the year 2025, Aurinia Pharmaceuticals had annual revenue of $283.06M with 20.38% growth. Aurinia Pharmaceuticals had revenue of $77.11M in the quarter ending December 31, 2025, with 28.81% growth.
Revenue (ttm)
$283.06M
Revenue Growth
+20.38%
P/S Ratio
6.73
Revenue / Employee
$2,211,367
Employees
128
Market Cap
1.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 283.06M | 47.92M | 20.38% |
| Dec 31, 2024 | 235.13M | 59.62M | 33.97% |
| Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
| Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
| Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
| Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
| Dec 31, 2019 | 318.00K | -145.00K | -31.32% |
| Dec 31, 2018 | 463.00K | 45.00K | 10.77% |
| Dec 31, 2017 | 418.00K | 245.00K | 141.62% |
| Dec 31, 2016 | 173.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 673.00M |
| Iovance Biotherapeutics | 263.50M |
| Stoke Therapeutics | 205.63M |
| Soleno Therapeutics | 190.41M |
| Syndax Pharmaceuticals | 172.35M |
| Recursion Pharmaceuticals | 74.68M |
| Mesoblast | 65.38M |
| Nektar Therapeutics | 62.60M |
AUPH News
- 9 days ago - Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets - Benzinga
- 9 days ago - Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress - Business Wire
- 16 days ago - Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 - Business Wire
- 4 months ago - Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress - Business Wire
- 4 months ago - Wall Street Breakfast Podcast: FDA Executive Controversy - Seeking Alpha
- 4 months ago - Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Business Wire